In drug development, you must know more than science.

Board of Directors

Heng-Tong Choo, Director

Heng-Tong, who joined Bio*One Capital in 2003, is focused on biotechnology and medical device investments in eastern US companies. He is actively involved with Bio*One portfolio companies, including A-Bio Pharma, CombinatoRx and Vanda Pharmaceuticals.

Prior to joining Bio*One Capital, Heng-Tong was Director of Chicago Center, Singapore Economic Development Board, where he worked with health care companies such as Eli Lilly, Procter & Gamble Pharmaceutical and GE Healthcare to develop their operations in Singapore.

Heng-Tong earned his masters in biotechnology from Columbia University and his masters in engineering from Imperial College, London.